Orthofix Medical Inc. maintains a dedicated global workforce comprising approximately 1,300 to 1,600 employees worldwide. The majority of its personnel are concentrated across North America and Southern/Western Europe, supporting specialized departments spanning engineering, research and development, clinical regulatory affairs, global sales, and medical education initiatives tailored for spine and orthopedic solutions.
Revo Health operates as a prominent management services organization partnering with specialized healthcare practices like Twin Cities Orthopedics.
When referring to pharmaceutical products like the OFIX tablet (which contains the fluoroquinolone antibiotic ofloxacin), potential side effects can include gastrointestinal discomfort such as nausea, mild diarrhea, abdominal cramps, headaches, dizzi...
The Ofix 200 Tablet is a prescription fluoroquinolone antibiotic containing 200mg of ofloxacin as its active pharmaceutical ingredient.
Yes, Medicare generally covers bone growth stimulators, but coverage is strictly regulated and contingent upon meeting precise medical necessity criteria.
The corporate net worth or market capitalization of Orthofix Medical Inc. (NASDAQ: OFIX) fluctuates dynamically during active trading hours on the Nasdaq exchange based on share price changes and total outstanding common stock.
Bone growth stimulators are generally considered exceptionally safe medical devices with minimal adverse side effects.
Depending on the context of your inquiry, OFIX can refer to multiple distinct entities. In financial markets, OFIX is the ticker symbol for Orthofix Medical Inc.
The out-of-pocket rental cost for a prescription bone growth stimulator varies significantly depending on health insurance coverage, Medicare provider fee schedules, and specific device models.
Orthofix Inc. previously faced high-profile federal scrutiny and a major whistleblower False Claims Act lawsuit that resulted in a $42 million global criminal and civil resolution with the U.S. Department of Justice.
Clinical studies evaluating non-invasive bone growth stimulators (which utilize pulsed electromagnetic field or low-intensity ultrasound technology to promote healing in non-union fractures or spinal fusions) generally report high clinical success ra...
The "best" bone growth stimulator is determined by a physician's prescription based on the specific type of fracture, non-union status, or spinal fusion site.
The global orthopedic and medical device market features several massive multinational corporations competing for top market share.
No, Orthofix Medical Inc. is not a private company. It is a publicly traded global medical technology enterprise listed on the Nasdaq Global Select Market under the ticker symbol OFIX.
Orthofix Medical Inc. is recognized as an established global medical technology enterprise dedicated to advancing spine and orthopedic care solutions.
The President and Chief Executive Officer of Orthofix Medical Inc. is Massimo Calafiore, who also serves as a member of the company's Board of Directors.
Orthofix Medical Inc. maintains its primary corporate headquarters and executive administrative offices in Lewisville, Texas, United States.
Supporting bone fracture healing and overall skeletal health through nutrition requires adequate intake of calcium, protein, and essential micronutrients.
Orthofix Medical Inc.
Clinical and scientific evidence demonstrates that Orthofix's medical devices and orthopedic systems achieve high rates of clinical efficacy when utilized according to strict manufacturer guidelines and physician instructions.
Wall Street equity research analysts covering Orthofix Medical Inc. (NASDAQ: OFIX) maintain a general consensus rating leaning toward a Buy.
Yes, Orthofix's core medical devices and bone growth therapy systems are FDA approved or cleared for commercial distribution and clinical use in the United States.
Orthofix Medical Inc. (NASDAQ: OFIX) generates robust annual net revenues scaling in the hundreds of millions of dollars, typically reporting total yearly revenues between $700 million and $750 million.
When discussing medical devices or orthopedic care frameworks, "Safix" (or similar variant terminology associated with casting, bandaging, or stabilization products) typically presents minimal localized risks.
The cost of an Orthofix bone growth stimulator (such as their proprietary spine or extremity therapy units) varies depending on insurance contractual agreements, Medicare fee schedules, and whether the device is rented or purchased.
Prescription bone growth stimulators are high-end medical devices, with retail purchase costs or monthly commercial rental fees ranging broadly from $2,000 to over $4,000 per month depending on the specific model and treatment duration required.